Results 31 to 40 of about 4,521 (193)

Filgotinib in Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis of Efficacy and Adverse Events. [PDF]

Healthcare (Basel)
Background: Filgotinib is an emerging Janus kinase 1 (JAK1) inhibitor being investigated for inflammatory bowel disease. This systematic review and network meta-analysis (NMA) evaluated the efficacy and safety of filgotinib in adult patients with ...
Khoshaim YA, Habis YZ, Daqnah AG, Alqurashi RK, Abdulrahim YS, Sakkat A, Alsubhi SA, Almuwlad DT, Bukhari HS, Shogdar AJ, Amir OA, Zaazouee MS.   +11 more
europepmc   +2 more sources

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjogren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study [PDF]

, 2022
OBJECTIVE: The aim of this study was to characterize the safety and efficacy of filgotinib, lanraplenib and tirabrutinib in patients with active SS. METHODS: This multicentre, double-blind study randomized patients with active primary or secondary SS ...
Bombardieri, M, Downie, B, Gottenberg, JE, Gurtovaya, O, Jiang, W, Kivitz, A, Mathur, A, Matzkies, F, Mozaffarian, A, Mozaffarian, N, Pechonkina, A, Price, E   +11 more
core   +1 more source

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

Clinical Pharmacology &Therapeutics, EarlyView.
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi, Andrea Pasta, Walter Elisei, Brigida Barberio, Giammarco Mocci, Giovanni Maconi, Antonietta Gerarda Gravina, Raffaele Pellegrino, Giorgia Bodini, Edoardo Vincenzo Savarino, Alfredo Papa, Italian Network for Inflammatory Bowel Diseases (IN‐IBD), Davide G. Ribaldone, Antonio Ferronato, Greta Lorenzon, Davide Checchin, Francesca Lambroglia, Francesco Ferrara, Carla Felice, Giovanni Cataletti, Giorgia Bodini, Andrea Pasta, Giovanni Aragona, Patrizia Perazzo, Federica Gaiani, Stefano Kayali, Fabio Cortellini, Francesco Costa, Lorenzo Bertani, Antonella Scarcelli, Mariaelena Serio, Emanuele Bendia, Laura Bolognini, Daniele Balducci, Claudia Quatraccioni, Francesco Martini, Michele Montori, Simona Piergallini, Francesca Maria Onidi, Paolo Usai Satta, Giorgia Orrù, Raffaele Colucci, Francesco Bachetti, Gabrio Bassotti, Elisabetta Antonelli, Costantino Zampaletta, Giulia Rocco, Carlotta Sacchi, Franco Scaldaferri, Daniele Napolitano, Roberto Faggiani, Michela Di Fonzo, Rita Monterubbianesi, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Roberta Pica, Maddalena Zippi, Andrea Cocco, Claudio Cassieri, Roberto Lorenzetti, Gian Marco Giorgetti, Valeria Clemente, Patrizio Scarozza, Girolamo Bevevino, Giulia Zerboni, Federico Iacopini, Giacomo Forti, Laurino Grossi, Serafina Fiorella, Giovanni Lombardi, Marta Patturelli, Giuliana Vespere, Silvia Sedda, Vittorio D’Onofrio, Leonardo De Luca, Caterina Mucherino, Elvira D’Antonio, Laura Montesano, Pietro Capone, Guido Daniele Villani, Antonio Cuomo, Laura Donnarumma, Nicola Della Valle, Giuseppe Pranzo, Paolo Tonti, Viviana Neve, Libera Fanigliulo, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefano Scorza, Manuela Marzo, Ileana Luppino, Francesco Luzza, Rocco Spagnuolo, Stefano Rodinò, Ladislava Sebkova, Antonio De Medici, Domenico Catarella, Dario D’Agostino, Elisabetta Di Bartolo   +100 more
wiley   +1 more source

Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis:An Evidence Review Group Perspective of a NICE Single Technology Appraisal [PDF]

, 2023
The National Institute for Health and Care Excellence invited the manufacturer (Galapagos) of filgotinib (Jyseleca®), as part of the Single Technology Appraisal process, to submit evidence for the clinical effectiveness and cost effectiveness of ...
Ahmadu, Charlotte, Armstrong, Nigel, Govers, Tim M., Grimm, Sabine E., Hoentjen, Frank, Joore, Manuela A., Kimman, Merel, McDermott, Kevin, Peeters, Andrea, Stirk, Lisa, van Asselt, Antoinette D.I.   +10 more
core   +1 more source

Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study

RMD Open
Objectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials.
René Westhovens, Kevin L Winthrop, A. Kavanaugh, Maria Greenwald, L. Dagna, R. Cseuz, R. Besuyen, Dick de Vries, V. Modgill, L. Le, M. Genovese, Paul Emery, P. Verschueren, R. Alten   +13 more
semanticscholar   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Prescription Behaviour and Drug Interactions of Acid Suppressants With Tyrosine Kinase Inhibitors in Patients With Leukaemia: Data From Germany

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Tyrosine kinase inhibitors (TKIs) are essential in treating chronic myeloid leukaemia (CML) and other malignancies. Their absorption, however, is highly pH‐dependent, making them susceptible to interactions with acid‐suppressing agents such as proton pump inhibitors (PPIs), histamine‐2 receptor antagonists (H2RAs) and antacids ...
Marek Lapka, Anna Khryakova, Anastasiia Nazmutdinova, Chrysostomos Charalambous, Jan Bosak, Jiri Sliva   +5 more
wiley   +1 more source

P50 addressing the vocational development of young people with long-term health conditions in health care settings:a systematic review and mixed methods synthesis [PDF]

, 2022
INTRODUCTION/BACKGROUND: Long term health conditions (LTHC) such as rheumatic conditions have significant impact on the biopsychosocial development of young people (YP) including vocational development.
Farre, Albert, Lee, Rebecca R., Lunt, Laura, McDonagh, Janet E., Verstappen, Suzanne   +4 more
core   +2 more sources

Continuous Treatment with Tofacitinib but Not Filgotinib Is Effective in Non-Responders with Active Ulcerative Colitis: A Propensity Score-Matching Analysis

Journal of Clinical Medicine
Background: Few studies have compared the efficacy and safety of Janus kinase (JAK) inhibitors in patients with ulcerative colitis (UC). We compared the real-world effectiveness and safety of tofacitinib (TOF) and filgotinib (FIL) as induction therapy ...
S. Yagi, H. Fukui, M. Ikenouchi, T. Shiraishi, K. Kaku, Midori Wakita, Y. Takagi, Toshiyuki Sato, M. Kawai, K. Kamikozuru, Y. Yokoyama, T. Takagawa, T. Tomita, S. Shinzaki   +13 more
semanticscholar   +1 more source

Cholesterol Promotes Lung Adenocarcinoma Brain Metastasis by Stabilizing EGFR Protein to Drive EMT, Metabolic Reprogramming, and Premetastatic Niche Formation

Advanced Science, Volume 13, Issue 17, 23 March 2026.
Cholesterol is revealed as a multitasking fuel for lung adenocarcinoma brain metastasis: it locks EGFR at the membrane to sustain AKT/NF‐κB–driven glycolysis and EMT, loosens the blood–brain barrier by promoting Claudin‐5 loss, and rewires microglia through IL‐4R lipid‐raft–JAK1/STAT6 signaling.
Ying Chen, Xiaoteng Cui, Xinyi Shi, Xu Yang, Yujing Cao, Haolin LI, Qi Zhan, Qixue Wang, Ang Li, Qihong Cheng, Yunfei Wang, Junhu Zhou, MingJie Wang, Chunsheng Kang, Xiaomin Liu   +14 more
wiley   +1 more source